Trial Profile
A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2015
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Head and neck cancer
- Focus Registrational; Therapeutic Use
- Acronyms NICAP
- Sponsors Eurofarma
- 24 Jul 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 15 Aug 2013 Planned number of patients changed from 304 to 280 as reported by ClinicalTrials.gov.
- 15 Aug 2013 Planned initiation date changed from 1 Sep 2011 to 1 Nov 2013 as reported by ClinicalTrials.gov.